Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (341)	4/21/1999 11:43:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 3158

Yeah, I caught the CEO of Amgen on CNBC this morning...they gave him a good grilling on the Amgen pipeline. The interview certainly made it sound as though Amgen is shopping for platforms...whenever I hear a fellow talking about needles my thoughts go back to the gene therapy companies. Sure wish Hoechst or Amgen would do something for my Ariad stock. I wonder if ARGENT would be worth $12 a share to either, silly, but fun to wish. Well, time for something useful...here is an url to biocentury...this week, we have a suggestion that Elan will probably sit out for a year and digest. biocentury.com Elan's venture adventure